Friday, 20 February 2026 BB Biotech FY 2025 results release — FY 2025 analyst conference call: 20 February 2026 at 10.00am CET – [join Webscast]
Friday, 20 February 2026 BB Biotech FY 2025 results release — FY 2025 analyst conference call: 20 February 2026 at 10.00am CET – [join Webscast]
Update your browser to view this website correctly.
Biotechnology is a key technology of the 21st century and a central driver of future healthcare. Scientific breakthroughs, structural demand and global innovation are creating long-term investment opportunities across the sector.
Biotechnology is transforming how diseases are understood and treated. Advances in areas such as genetic medicine, RNA-based therapies, cell therapies and precision oncology are enabling breakthrough treatments that can redefine standards of care.
Scientific innovation is the primary source of value creation in biotechnology, with successful therapies often delivering meaningful medical impact and long-term economic value.
The sector benefits from strong structural growth drivers. Aging populations, rising prevalence of chronic and complex diseases, and significant unmet medical needs are supporting sustained global demand for innovative therapies.
Healthcare systems increasingly prioritize treatments with clear medical benefit, reinforcing long-term adoption for differentiated biotechnology innovation.
Above-average return potential
For long-term investors, biotechnology offers attractive return potential driven by innovation-led growth. Value creation is closely linked to key inflection points such as clinical milestones, regulatory approvals and successful product launches.
At the same time, the sector shows high dispersion between winners and losers, making selectivity and a long-term perspective essential.
Large pharmaceutical companies face a significant patent cliff and increasingly rely on external innovation to sustain future growth. Biotechnology companies play a central role as sources of innovation for partnerships and acquisitions.
This dynamic supports sustained M&A activity across the sector and provides an additional pathway for value realization alongside public markets.
"Biotechnology combines innovation, structural growth and long-term demand with multiple pathways to value creation. For investors willing to take a long-term perspective, the sector represents a compelling opportunity to participate in the future of medicine."
